Longeveron Future Growth
Future criteria checks 5/6
Longeveron is forecast to grow earnings and revenue by 55.5% and 54.7% per annum respectively while EPS is expected to grow by 59.1% per annum.
Key information
55.5%
Earnings growth rate
59.14%
EPS growth rate
| Biotechs earnings growth | 25.1% |
| Revenue growth rate | 54.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 May 2026 |
Recent future growth updates
Recent updates
LGVN: Upcoming HLHS Trial Outcome Will Drive Upside Potential
Analysts have raised their price target on Longeveron from $5.82 to $7.15, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E, even as some recent Street research has become more cautious on the stock. What’s in the News for Longeveron Longeveron received Small or Medium sized Enterprise status from the European Medicines Agency, giving the company access to scientific advice, regulatory guidance, and reduced administrative fees during clinical development in Europe.
LGVN: Nasdaq Compliance Extension And Trial Progress Will Support Future Repricing
Analysts have trimmed their price target on Longeveron by $1 to reflect slightly different assumptions on the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bearish analysts recently trimmed their Longeveron price target by US$1, citing changes in assumptions for discount rates, revenue growth, profit margins, and future P/E expectations.LGVN: Nasdaq Compliance Extension And Clinical Progress Will Support Future Repricing
Analysts have lowered their price target on Longeveron by $1, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts cutting the price target by $1 are signaling a more cautious stance on what they see as Longeveron’s risk and reward tradeoff.LGVN: ELPIS II Pivotal Trial And Nasdaq Extension Will Drive Future Repricing
Analysts trimmed their price target on Longeveron by $1, citing updated assumptions that now reflect a fair value of 2.0, a discount rate of 7.08457895304031, revenue growth of 37.91869977802995, a profit margin of 14.774604420000001, and a future P/E of 147.96681297821388. Analyst Commentary Bearish analysts trimming the price target by $1 are signaling that, in their view, the updated assumptions justify a more conservative stance on Longeveron.LGVN: Upcoming HLHS Trial Meeting Will Drive Upside Potential
Analysts trimmed their price target on Longeveron to $5.82, reflecting updated assumptions that include a slightly lower discount rate, revised profit margin expectations, and a higher projected P/E multiple in their models. What's in the News Longeveron entered a definitive agreement for a private placement with Coastlands Capital, Janus Henderson Investors, Logos Capital and Kalehua Capital, targeting gross proceeds of US$30 million through Class A common stock and Series A Non Voting Convertible Preferred Stock.LGVN: Upcoming HLHS Meeting And Trial Pathway Will Drive Upside Potential
Analysts have adjusted their price target for Longeveron, maintaining it at $5.82, as they revisit assumptions around future revenue growth, profit margins, discount rate, and expected P/E. These revisions reflect a more balanced view of the company's long term potential and risk profile.LGVN: Upcoming HLHS Trial Readout Will Drive Future Upside Potential
Analysts have lowered their price target on Longeveron from about $6.86 to roughly $5.82. They now factor in a higher discount rate, stronger revenue growth expectations, a lower profit margin outlook, and a slightly higher future P/E multiple.FDA Alignment And HLHS Trial Will Enable Market Access
Longeveron's valuation outlook has strengthened, with a sharp drop in its forward P/E multiple and improved net profit margin indicating better profitability and a more attractive risk-reward profile, though the consensus analyst price target remains unchanged at $8.39. What's in the News Longeveron completed a $17.5 million follow-on equity offering, issuing 5.62 million shares of Class A common stock, 14.71 million warrants, and 265,000 pre-funded warrants at $0.85 per security.Can Longeveron (NASDAQ:LGVN) Afford To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
ELPIS II And Alzheimer Programs Will Accelerate FDA Approval
Successful trial enrollment and regulatory designations could accelerate Longeveron's market entry and future revenue growth through streamlined FDA pathways and partnerships.Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 41 | -1 | N/A | N/A | 2 |
| 12/31/2027 | 7 | -24 | N/A | N/A | 4 |
| 12/31/2026 | 1 | -22 | N/A | N/A | 4 |
| 3/31/2026 | 1 | -22 | -19 | -18 | N/A |
| 12/31/2025 | 1 | -23 | -19 | -19 | N/A |
| 9/30/2025 | 1 | -21 | -17 | -17 | N/A |
| 6/30/2025 | 2 | -19 | -16 | -15 | N/A |
| 3/31/2025 | 2 | -26 | -17 | -15 | N/A |
| 12/31/2024 | 2 | -25 | -15 | -14 | N/A |
| 9/30/2024 | 2 | -27 | -16 | -14 | N/A |
| 6/30/2024 | 1 | -28 | -17 | -16 | N/A |
| 3/31/2024 | 1 | -22 | -17 | -16 | N/A |
| 12/31/2023 | 1 | -22 | -20 | -19 | N/A |
| 9/30/2023 | 1 | -21 | -18 | -17 | N/A |
| 6/30/2023 | 1 | -20 | -18 | -17 | N/A |
| 3/31/2023 | 1 | -20 | -17 | -16 | N/A |
| 12/31/2022 | 1 | -19 | -15 | -14 | N/A |
| 9/30/2022 | 1 | -18 | -15 | -13 | N/A |
| 6/30/2022 | 1 | -18 | -12 | -11 | N/A |
| 3/31/2022 | 1 | -17 | -12 | -11 | N/A |
| 12/31/2021 | 1 | -17 | -11 | -10 | N/A |
| 9/30/2021 | 2 | -14 | -9 | -9 | N/A |
| 6/30/2021 | 4 | -10 | -7 | -7 | N/A |
| 3/31/2021 | 4 | -7 | -5 | -5 | N/A |
| 12/31/2020 | 6 | -4 | -3 | -2 | N/A |
| 9/30/2020 | 6 | -3 | -2 | -2 | N/A |
| 12/31/2019 | 6 | -3 | N/A | -2 | N/A |
| 12/31/2018 | 2 | -6 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LGVN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).
Earnings vs Market: LGVN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: LGVN is expected to become profitable in the next 3 years.
Revenue vs Market: LGVN's revenue (54.7% per year) is forecast to grow faster than the US market (12.7% per year).
High Growth Revenue: LGVN's revenue (54.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LGVN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 04:11 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Longeveron Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| Michael Okunewitch | Maxim Group |